Idex CORP /DE/ 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NYSE
IDEX Corporation announced a 6% increase in net sales and an 11% rise in diluted EPS for the second quarter of 2026, driven by strong performance in its Health & Science Technologies segment.
NYSE
IDEX Corporation announced a 10% increase in reported net sales and an 8% rise in diluted EPS for Q3 2025, driven by acquisitions and organic growth, despite challenging macroeconomic conditions.
NYSE
IDEX Corporation reported a 7% increase in net sales for Q2 2025, driven by acquisitions, while organic sales growth remained modest and diluted EPS declined due to higher interest and amortization costs.
NYSE
IDEX Corporation's first quarter 2025 results show a net sales increase of 2% but a decrease of 21% in diluted earnings per share, impacted by acquisition-related costs and market conditions.
NYSE
IDEX Corporation's third-quarter results show a slight increase in net sales but a significant decrease in net income, impacted by market softness and acquisition costs, while the company completed the acquisition of Mott Corporation.
NYSE
IDEX Corporation's second quarter 2024 results show a decrease in net sales, but solid operating performance with strong price/cost and productivity.
NYSE
IDEX Corporation's first quarter 2024 results show a decrease in sales and earnings compared to the previous year, but the company generated strong cash flow from operations.